ASCO Updates Managing Brain Metastases in HER2-Positive Disease
Recently, the American Society of Clinical Oncology (ASCO) updated its guidelines on the management of brain metastases (BM) in patients with human epidermal growth factor receptor 2 (HER2)–positive (+) advanced breast cancer (BC). The update includes systematic review-based recommendations for systemic therapy as well as consensus-based recommendations for radiation therapy and/or surgery for HER2+ BC with BM. Read more.

Role of Platinum-Based Therapy in TNBC
Triple-negative breast cancer (TNBC), which accounts for 10% to 20% of breast cancer (BC), is an aggressive form of BC that is estrogen and progesterone receptor-negative and human epidermal growth factor receptor 2-negative. It is difficult to treat and more often found in younger patients. Learn more about the role platinum-based therapies take on in treating TNBC.

Multicenter Study of CDK4/6 Inhibitors in Male BC
Male breast cancer (BC) accounts for fewer than 1% of all BC diagnoses, with 80% of cases being hormone-receptor positive (HR+) and human epidermal growth factor receptor 2-negative. Given the rarity of the disease, it is difficult to conduct phase III clinical trials to assess treatment regimens. Learn more about the role cyclin-dependent kinase 4/6 (CDK4/6) inhibitors play in patient survival.